Coleman Lannum

Biography

Coleman (Cole) Lannum is the senior vice president of investor strategy and investor relations officer at Mallinckrodt Pharmaceuticals. He has responsibility for integrating investor relations with all corporate strategic functions and strengthening investor relations communications both internally and throughout the broader investment community. Mr. Lannum is a member of Mallinckrodt’s finance leadership team. Prior to joining Mallinckrodt in 2015, Mr. Lannum led investor relations at Covidien and Tyco, where he served as Vice President and Investor Relations Officer. During his nine years at Covidien, Mr. Lannum’s leadership was recognized with an unprecedented number of investor relations best-in-class awards from 2008-2015, including best investment community meetings, best earnings calls, and best financial reporting. Previously, Mr. Lannum held investment leadership roles at Putnam Investments, as well as Boatmen’s Trust and American Express Asset Management (both now part of Columbia Asset Management). Coleman (Cole) Lannum is the senior vice president of investor strategy and investor relations officer at Mallinckrodt Pharmaceuticals. He has responsibility for integrating investor relations with all corporate strategic functions and strengthening investor relations communications both internally and throughout the broader investment community. Mr. Lannum is a member of Mallinckrodt’s finance leadership team. Prior to joining Mallinckrodt in 2015, Mr. Lannum led investor relations at Covidien and Tyco, where he served as Vice President and Investor Relations Officer. During his nine years at Covidien, Mr. Lannum’s leadership was recognized with an unprecedented number of investor relations best-in-class awards from 2008-2015, including best investment community meetings, best earnings calls, and best financial reporting. Previously, Mr. Lannum held investment leadership roles at Putnam Investments, as well as Boatmen’s Trust and American Express Asset Management (both now part of Columbia Asset Management).

Research Interest

Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry